Excellergy Inc.
3 known investors
Find your way into Excellergy Inc.
Sign up to see every warm intro you have to Excellergy Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Excellergy Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Excellergy develops a new class of allergy therapeutics called allergic Effector Cell Response Inhibitors (ECRIs), biologics that use a trifunctional mechanism to remove IgE bound to effector cells, neutralize circulating IgE, and downregulate FcεRI receptors for treating severe allergic diseases. The preclinical-to-clinical stage biotech became an indirect, wholly owned subsidiary of Novartis AG and is advancing a portfolio of first-in-class anti-IgE drug candidates.
Founders & leadership
AE
Alex EggelCo-founder & Scientific Consultant
TJ
Ted JardetzkyCo-founder
LP
Luke PenningtonCo-founder
GH
Geoff HarrisCo-founder & CSO
TZ
Todd ZavodnickCEO
PB
Phil BrownChief Medical Officer
TH
Travis H. TaniSVP of Technical Operations & Quality
Investors · 3
Frequently asked questions
- What does Excellergy Inc. do?
- Excellergy develops a new class of allergy therapeutics called allergic Effector Cell Response Inhibitors (ECRIs), biologics that use a trifunctional mechanism to remove IgE bound to effector cells, neutralize circulating IgE, and downregulate FcεRI receptors for treating severe allergic diseases. The preclinical-to-clinical stage biotech became an indirect, wholly owned subsidiary of Novartis AG and is advancing a portfolio of first-in-class anti-IgE drug candidates.
- Who are Excellergy Inc.'s investors?
- Excellergy Inc.'s investors include Red Tree Venture Capital, Decheng Capital, Samsara BioCapital.

